Publications

Key Published Literature

Anti-PlGF

Van de Veire S, Stalmans I, Heindryckx F, et al. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell. 2010;141(1):178-190.

Fischer C, Mazzone M, Jonckx B, et al. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer. 2008;8(12):942-956. Review.

Fischer C, Jonckx B, Mazzone M, et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell. 2007;131(3):463-475. http://www.ncbi.nlm.nih.gov/pubmed/17981115

Loges S, Schmidt T, Carmeliet P. “Antimyeloangiogenic” therapy for cancer by inhibiting PlGF. Clin Cancer Res. 2009;15(11):3648-3653. http://www.ncbi.nlm.nih.gov/pubmed/19470735

Luttun A, Autiero M, Tjwa M, Carmeliet P. Genetic dissection of tumor angiogenesis: are PlGF and VEGFR-1 novel anti-cancer targets? Biochim Biophys Acta. 2004;1654(1):79-94. http://www.ncbi.nlm.nih.gov/pubmed/14984769

Van Steenkiste C, Geerts A, Vanheule E, et al. Role of placental growth factor in mesenteric neoangiogenesis in a mouse model of portal hypertension. Gastroenterology. 2009;137(6):2112-2124.e1-6. http://www.ncbi.nlm.nih.gov/pubmed/19751735